Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 13/20 | 0.85 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.85 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.85 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.85 |
| ▸ | RAF1 | P04049 | 5/20 | 0.85 |
| ▸ | GCGR | P47871 | 8/20 | 0.83 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.68 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127491 | 1.00 | MAPK13 (0.85) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL9748575 | 0.93 | MAPK13 (0.83) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5921859 | 0.92 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6469111 | 0.92 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5074753 | 0.91 | MAPK13 (0.83) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL16667652 | 0.89 | MAPK13 (0.83) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL104130 | 0.89 | MAPK13 (0.82) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| Benzene SCHEMBL28852698 | 0.89 | MAPK13 (0.82) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL28149842 | 0.89 | MAPK13 (0.69) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| Methane SCHEMBL3278320 | 0.87 | MAPK13 (0.79) | MAPK13MAPK12MAPK11MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999701-B1 | 4,5-bis(4-chlorophenyl)-2-phenyl-1H-imidazol-1-yl as an antimicrobial compound | King Faisal University (SA) | 2024-06-04 | — | — | US | claimed |
| US-11999701-B1 | 4,5-bis(4-chlorophenyl)-2-phenyl-1H-imidazol-1-yl as an antimicrobial compound | King Faisal University (SA) | 2024-06-04 | — | — | US | disclosed |
| US-11999701-B1 | 4,5-bis(4-chlorophenyl)-2-phenyl-1H-imidazol-1-yl as an antimicrobial compound | King Faisal University (SA) | 2024-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999701-B1 | 4,5-bis(4-chlorophenyl)-2-phenyl-1H-imidazol-1-yl as an antimicrobial compound | IL4, CASP4, NFKBIA | MAPK13 614/4885MAPK12 675/4885MAPK11 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.